Newer insulin analogs: advances in basal insulin replacement

The worldwide diabetes epidemic

(2013) David W. Lam et al.   Current Opinion in Endocrinology Diabetes and Obesity

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

(2012) Fei Wang et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

(2011) K. I. Birkeland et al.   DIABETES CARE

Globalization of Diabetes: The role of diet, lifestyle, and genes

(2011) F. B. Hu   DIABETES CARE

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

(2011) Bernard Zinman et al.   LANCET

Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials

(2010) Patrick Murray et al.   Current Atherosclerosis Reports

Barriers to Insulin Initiation: The Translating Research Into Action for Diabetes Insulin Starts Project

(2010) A. J. Karter et al.   DIABETES CARE

Correlates of Insulin Injection Omission

(2010) M. Peyrot et al.   DIABETES CARE

US Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes

(2010) Fadia T. Shaya et al.   Journal of Clinical Hypertension

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes

(2009) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)

(2008) J.-P. Le Floch et al.   DIABETES CARE

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETOLOGIA